Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein–specific T cells in Lung Transplant Recipients

Abstract

J.H. and T.K. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis, and they participated in drafting of the article, statistical analysis, and data visualization.

Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients

“… 5 , 6 , 7 , 8 , 9 , 10 , 11 Previous studies showed that around half of solid organ recipients who were non-responders to the second dose seroconverted after a third mRNA vaccine dose, given as booster. 12 , 13 , 14 , 15 However, only few studies have determined the effectiveness of a third vaccine dose in LTR, 16 , 17 and markers predictive of vaccine response are still lacking. In order to quantify the impact of immunosuppression on vaccine response and hopefully to predict response or nonresponse, one should be able to quantify the level of immunosuppression.…”

Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients

“…Indeed, the observed serologic response in lung transplant recipients after two doses of an mRNA-based SARS-CoV-2 vaccine is poor [ 1 ]. It is recommended to give a third vaccine dose to all solid organ transplant recipients [ 2 ], but there are few reports on the serologic response to a third vaccine dose in lung transplant recipients specifically [ [3] , [4] , [5] ]. We previously reported on the serologic response to two doses of an mRNA-based SARS-CoV-2 vaccine in 91 lung transplant recipients [ 1 ].…”

Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy

“…In addition, the duration of detectable immune responses was comparable to that in a healthy population ( 14 – 16 ). Therefore, the biological drugs used to treat the patients in this study are different from other immunomodulatory drugs, which have been shown to compromise the immunogenicity of the COVID-19 vaccine ( 51 – 53 ).…”